{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T06:01:20Z","timestamp":1744783280562},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its intravenous formulation, has been used since 2006 for the treatment of CMML,\u00a0use of its oral formulation has been limited by poor bioavailability due to first-pass metabolism by the enzyme cytidine deaminase. The dose of intravenous decitabine is limited by toxicities such as cardiomyopathy and heart failure. Therefore, cedazuridine was developed as an inhibitor of cytidine deaminase. Cedazuridine decreases the first-pass metabolism of oral decitabine allowing therapeutic levels to be achieved at lower doses, and thus, the novel oral combination of cedazuridine with decitabine was developed. While cardiomyopathy and heart failure are well-established adverse effects associated with intravenous decitabine alone, there to our knowledge there have been no documented incidences of reversible cardiomyopathy in the literature or in patients who participated in the phase 2 and phase 3 clinical trials of oral decitabine-cedazuridine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case<\/jats:title>\n                <jats:p>This case study presents an 85\u2009year-old\u00a0Caucasian\u00a0female with CMML who developed cardiomyopathy and heart failure with reduced ejection fraction after completing 5\u2009cycles of therapy with decitabine\/cedazuridine. Furthermore, her symptoms and cardiac function recovered upon discontinuation of the drug.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We present an occurrence of reversible cardiomyopathy in a patient who completed 5\u2009cycles of decitabine\/cedazuridine, an oral combination therapy developed to enhance oral bioavailability of decitabine thereby limiting its adverse effects. As the decitabine\/cedazuridine combination therapy rises in popularity due to its convenient oral formulation, more trials are needed to understand the prevalence of cardiomyopathy with this drug and to discover preventative strategies for cardiotoxic effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-023-00153-6","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T07:02:59Z","timestamp":1674025379000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine\/cedazuridine: a case report"],"prefix":"10.1186","volume":"9","author":[{"given":"Ankur","family":"Sheel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junu","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashlee","family":"Asada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragavendra R.","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin L.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"1","key":"153_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.seminhematol.2007.11.007","volume":"45","author":"EA Griffiths","year":"2008","unstructured":"Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008;45(1):23\u201330.","journal-title":"Semin Hematol"},{"issue":"4","key":"153_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2009.23.4781","volume":"28","author":"L Shen","year":"2010","unstructured":"Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605.","journal-title":"J Clin Oncol"},{"issue":"12","key":"153_CR3","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1158\/0008-5472.CAN-06-0080","volume":"66","author":"SD Gore","year":"2006","unstructured":"Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12):6361\u20139.","journal-title":"Cancer Res"},{"issue":"11","key":"153_CR4","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1002\/cncr.23463","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008;112(11):2341\u201351.","journal-title":"Cancer"},{"issue":"8","key":"153_CR5","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel AA, Cahill K, Saygin C, Odenike O. Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021;5(8):2264\u201371.","journal-title":"Blood Adv"},{"issue":"21","key":"153_CR6","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood.V118.21.3801.3801","volume":"118","author":"B Mistry","year":"2011","unstructured":"Mistry B, Jones MM, Kubiak P, et al. A phase I study to assess the absolute bioavailability and safety of an oral solution of decitabine in subject with myelodysplastic syndromes (MDS). Blood. 2011;118(21):3801.","journal-title":"Blood."},{"issue":"18","key":"153_CR7","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","volume":"29","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29(18):2521\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"153_CR8","first-page":"807","volume":"3","author":"HI Saba","year":"2007","unstructured":"Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007;3(5):807.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"153_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/leu.2017.186","volume":"32","author":"V Santini","year":"2018","unstructured":"Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413\u20138.","journal-title":"Leukemia."},{"key":"153_CR10","doi-asserted-by":"publisher","first-page":"3953579","DOI":"10.1155\/2018\/3953579","volume":"2018","author":"P Agasthi","year":"2018","unstructured":"Agasthi P, Narayanasamy H, Sorajja D, Slack J, Mookadam F. Decitabine induced delayed cardiomyopathy in hematologic malignancy. Case Rep Cardiol. 2018;2018:3953579. https:\/\/doi.org\/10.1155\/2018\/3953579.","journal-title":"Case Rep Cardiol"},{"issue":"6","key":"153_CR11","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.2019004143","volume":"136","author":"G Garcia-Manero","year":"2020","unstructured":"Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, et al. Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study. Blood. 2020;136(6):674\u201383.","journal-title":"Blood."},{"issue":"4","key":"153_CR12","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(19)30030-4","volume":"6","author":"MR Savona","year":"2019","unstructured":"Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019;6(4):e194\u2013203.","journal-title":"Lancet Haematol"},{"issue":"4","key":"153_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/1078155217702213","volume":"24","author":"LB Levine","year":"2018","unstructured":"Levine LB, Roddy JV, Kim M, Li J, Phillips G, Walker AR. A comparison of toxicities in acute myeloid leukemia patients with and without renal impairment treated with decitabine. J Oncol Pharm Pract. 2018;24(4):290\u20138.","journal-title":"J Oncol Pharm Pract"},{"key":"153_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4137\/CMO.S8598","volume":"6","author":"C De","year":"2012","unstructured":"De C, Phookan J, Parikh V, et al. Decitabine induced transient cardiomyopathy: a case report. Clin Med Insights Oncol. 2012;6:325\u20139. https:\/\/doi.org\/10.4137\/CMO.S8598.","journal-title":"Clin Med Insights Oncol"},{"issue":"6","key":"153_CR15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1021\/tx900131u","volume":"22","author":"DK Rogstad","year":"2009","unstructured":"Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, et al. Chemical decomposition of 5-aza-2\u2032-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol. 2009;22(6):1194\u2013204.","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"153_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/bcp.13849","volume":"85","author":"R Cohen","year":"2019","unstructured":"Cohen R, Preta LH, Joste V, Curis E, Huillard O, Jouinot A, et al. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours. Br J Clin Pharmacol. 2019;85(6):1227\u201338.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"153_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2009.24.4491","volume":"28","author":"J Ciccolini","year":"2010","unstructured":"Ciccolini J, Dahan L, Andr\u00e9 N, Evrard A, Duluc M, Blesius A, et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J Clin Oncol. 2010;28(1):160\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"153_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1046\/j.1365-2141.1998.01084.x","volume":"103","author":"JK Schr\u00f6der","year":"1998","unstructured":"Schr\u00f6der JK, Christoph K, Siegfried S, Jochen S. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol. 1998;103(4):1096\u2013103.","journal-title":"Br J Haematol"},{"issue":"1","key":"153_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/leu.2013.269","volume":"28","author":"F Traina","year":"2014","unstructured":"Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78\u201387.","journal-title":"Leukemia"},{"issue":"17","key":"153_CR20","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, P\u00e9rez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312.","journal-title":"Blood"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-023-00153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-023-00153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T07:16:50Z","timestamp":1674026210000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-023-00153-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["153"],"URL":"https:\/\/doi.org\/10.1186\/s40959-023-00153-6","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical images was obtained from the patient\/parents\/guardian\/relative of the patient. A copy of the consent form is available for review upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest or competing interest in relation to the work presented in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}